RE

Renalytix PLCLSE Renalytix Stock Report

Last reporting period 30 Jun, 2023

Updated 08 Nov, 2024

Last price

Market cap $B

0.021

Micro

Exchange

XLON - London Stock Exchange

RENX.L Stock Analysis

RE

Uncovered

Renalytix PLC is uncovered by Eyestock quantitative analysis.

Rating

To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.

-44/100

Low score

Market cap $B

0.021

Dividend yield

Shares outstanding

93.781 B

Renalytix Plc manufactures medical devices and equipment. The company is headquartered in Penarth, South Glamorgan and currently employs 110 full-time employees. The company went IPO on 2018-11-06. The firm is focused on optimizing clinical management of kidney disease to drive improved patient outcomes and advance value-based care. Its diagnostic platform, KidneyIntelX, is designed to scale across kidney disease conditions beyond diabetic kidney disease. KidneyIntelX is a bioprognostic methodology. The firm is evaluating a range of new indications in chronic kidney disease, cardio-renal disease, chronic kidney disease in diverse populations, and coronavirus disease (COVID)-related kidney disease. KidneyIntelX platform facilitates the identification and promotes the effective management of patients at risk of early-stage diabetic kidney disease (DKD), progression by combining diverse data inputs, including validated blood-based biomarkers, inherited genetics, and personalized patient data from electronic health record (HER) using a proprietary algorithm to generate a unique patient risk score.

View Section: Eyestock Rating